Equity · Healthcare
ARQT
NASDAQArcutis Biotherapeutics (ARQT)
The line runs 26 USD on 12 August through 26.22 USD on 9 November, on a scale from 20 to 35. Days the market did not trade hold the previous close, flat.
- Market cap
- 3.3B USD
- P/E (TTM)
- 119.2
- Revenue, year to Dec 2025
- 372.1M USD
- EPS, diluted, year to Dec 2025
- −0.13 USD
- 52-week range
- 19.38 USD – 32.80 USD
- Avg volume
- 165.8K
as of Nov 9, 2026
Have Arcutis Biotherapeutics (ARQT) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Arcutis Biotherapeutics insiders reported 13 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 6 Nov 2025, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 4 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 04 Nov 2026 | Matsuda MasaruEVP, Chief Legal Officer | Sell | 40,000 | 1.4M USD |
| 02 Nov 2026 | Watanabe ToddSee Remarks | Sell | 4,377 | 139K USD |
| 02 Nov 2026 | Burnett PatrickEVP, Chief Medical Officer | Sell | 943 | 30K USD |
| 02 Nov 2026 | Matsuda MasaruEVP, Chief Legal Officer | Sell | 1,219 | 39K USD |
| 15 Oct 2026 | Welgus Howard G.Director | Sell | 4,728 | 127K USD |
| 16 Sep 2026 | Matsuda MasaruSee Remarks | Sell | 3,674 | 92K USD |
| 15 Sep 2026 | Welgus Howard G.Director | Sell | 4,730 | 114K USD |
| 08 Sep 2026 | Matsuda MasaruSee Remarks | Sell | 9,989 | 250K USD |
| 27 Aug 2026 | Curran TerrieDirector | Sell | 38,200 | 956K USD |
| 20 Aug 2026 | Curran TerrieDirector | Sell | 1,072 | 28K USD |
| 19 Aug 2026 | Burnett PatrickSee Remarks | Sell | 1,697 | 46K USD |
| 17 Aug 2026 | Welgus Howard G.Director | Sell | 4,730 | 124K USD |
| Sold | 13 open-market sales | 122,059 | $3.49M |
Showing the 12 most recent of 13 open-market trades in this window. The figures above count all of them.
8 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 04 Nov 2026 | Matsuda MasaruEVP, Chief Legal Officer | Option exercise | 40,000 | 146K USD |
| 23 Oct 2026 | SCOTT ROBERT ADirector | Award | 2,819 | |
| 15 Oct 2026 | Welgus Howard G.Director | Option exercise | 4,094 | 32K USD |
| 15 Sep 2026 | Welgus Howard G.Director | Option exercise | 4,096 | 32K USD |
| 27 Aug 2026 | Curran TerrieDirector | Option exercise | 38,200 | 317K USD |
| 20 Aug 2026 | Curran TerrieDirector | Option exercise | 1,072 | 8K USD |
| 17 Aug 2026 | Welgus Howard G.Director | Option exercise | 4,096 | 32K USD |
| 12 Aug 2026 | Burnett PatrickSee Remarks | Option exercise | 6,700 | 24K USD |
Which funds hold Arcutis Biotherapeutics (ARQT)?
11 of the 45 institutional funds we track reported a Arcutis Biotherapeutics position for the quarter ended 30 Jun 2026 — a combined 209.9M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| D. E. Shaw & Co. | Added | 3,949,609 | 103.6M USD | +58.2% |
| Citadel Advisors | Added | 1,160,014 | 30.4M USD | +7,333.1% |
| Two Sigma Investments | Added | 663,877 | 17.4M USD | +183.3% |
| Millennium Management | Added | 564,072 | 14.8M USD | +1,043.4% |
| Marshall Wace | Trimmed | 446,866 | 11.7M USD | −81.6% |
| Point72 Asset Management | Trimmed | 362,449 | 9.5M USD | −38.7% |
| AQR Capital Management | Trimmed | 330,324 | 8.7M USD | −29.5% |
| Balyasny Asset Management | New position | 243,119 | 6.4M USD | |
| Tudor Investment Corp | New position | 131,914 | 3.5M USD | |
| Man Group | Added | 94,272 | 2.5M USD | +46.8% |
Showing the 10 largest of 11 reported positions. The figures above count all of them.
Have members of Congress traded Arcutis Biotherapeutics (ARQT)?
The most recent congressional trade disclosed in Arcutis Biotherapeutics is a sale by Gilbert Ray Cisneros, Jr. (house, CA), dated 11 Dec 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 11 Dec 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Sale | 1K USD–15K USD | 32 days |
| 15 Sep 2023 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 30 days |
| 17 Apr 2023 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 32 days |
| 15 Jun 2022 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 37 days |
What has been filed or recorded for Arcutis Biotherapeutics (ARQT)?
The filings we hold for Arcutis Biotherapeutics, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.06 USD | Revenue $144M |
| 30 Sep 2026 | Financials | Total assets | 524.4M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 244.0M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.11 USD | Revenue $130M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.09 USD | Revenue $105M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.13 USD | Revenue $376M |
| 31 Dec 2025 | Financials | Revenue | 372.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −16.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.13 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.06 USD | Revenue $99M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.13 USD | Revenue $82M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.20 USD | Revenue $66M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.16 USD | Revenue $197M |
What do people ask about Arcutis Biotherapeutics (ARQT)?
What did Arcutis Biotherapeutics shares close at?26.22
Arcutis Biotherapeutics closed at 26.22 USD on 9 Nov 2026, up 2.64% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Arcutis Biotherapeutics’ market cap?3.3B
Arcutis Biotherapeutics is worth 3.3B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Arcutis Biotherapeutics’ P/E ratio?119.2
Arcutis Biotherapeutics has a price-to-earnings ratio of 119.2, as of 9 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Arcutis Biotherapeutics’ revenue?372.1M
Arcutis Biotherapeutics reported revenue of 372.1M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Arcutis Biotherapeutics insiders bought or sold shares recently?13 sales
In the 90 days to 10 Nov 2026, Arcutis Biotherapeutics insiders reported 13 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 6 Nov 2025, show no open-market purchase. A further 8 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Arcutis Biotherapeutics?11 of 45
11 of the 45 funds we track reported a Arcutis Biotherapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were D. E. Shaw & Co., Citadel Advisors and Two Sigma Investments. See Funds
Have members of Congress traded Arcutis Biotherapeutics?4 trades
Yes. 4 trades in Arcutis Biotherapeutics appear in the congressional disclosures we hold; the latest is a sale by Gilbert Ray Cisneros, Jr. (House, CA) dated 11 Dec 2025, filed 12 Jan 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Arcutis Biotherapeutics last report earnings?0.06
Arcutis Biotherapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.06 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Gilbert Ray Cisneros, Jr.: United States Department of Defense, Public domain; Josh Gottheimer: Kristie Boyd; U.S. House Office of Photography, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings